Testing the effects of Qualia NAD+ on blood NAD+ levels
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels: A Randomized Double-Blind Parallel Trial
This study is testing if taking a supplement called Qualia NAD+ can raise NAD+ levels in the blood for people who participate.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 40 Years to 65 Years |
| Sex | All |
| Sponsor | Qualia Life Sciences Industry-sponsored |
| Locations | 1 site (Carlsbad, California) |
| Trial ID | NCT06505967 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of Qualia NAD+ supplementation in increasing NAD+ levels in the blood compared to a placebo. Participants will take either the supplement or placebo daily for four weeks and undergo blood tests before and after the intervention to measure changes in NAD+ levels. The study will also assess the safety of the supplement throughout the trial period.
Who should consider this trial
Good fit: Ideal candidates are healthy men and women aged 40-65 who are willing to comply with study requirements.
Not a fit: Patients who are currently taking supplements containing vitamin B3 or those outside the age range may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new approach to enhancing NAD+ levels, which may have implications for health and aging.
How similar studies have performed: While there is ongoing interest in NAD+ supplementation, this specific approach with Qualia NAD+ has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text. Healthy male and female participants between the ages of 40-65 years of age. Willingness to complete questionnaires, records, and diaries associated with the study. Willing to not consume any supplements, energy drinks/shots, or other products containing any form of supplemental vitamin B3 (e.g., niacin, niacinamide, nicotinamide ribosome, NMN) starting about 2 weeks prior to the baseline NAD fingerstick test and continuing through the intervention period. Willing to not begin taking any new supplements during the study period, and to continue taking any supplements they are currently using regularly (with the exception of vitamin B3 containing supplements). Willingness to self-administer the intracellular NAD fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives researchers access to the results of these tests. Exclusion criteria: Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent
Where this trial is running
Carlsbad, California
- Qualia Life Sciences — Carlsbad, California, United States (Recruiting)
Study contacts
- Study coordinator: William Scuba
- Email: support@qualialife.com
- Phone: 855-281-2328
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.